

(51) International Patent Classification:
A61K 9/00 (2006.01)(21) International Application Number:
PCT/US2018/055499(22) International Filing Date:
11 October 2018 (11.10.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/571,025	11 October 2017 (11.10.2017)	US
62/571,038	11 October 2017 (11.10.2017)	US
62/571,049	11 October 2017 (11.10.2017)	US
62/598,786	14 December 2017 (14.12.2017)	US
62/598,796	14 December 2017 (14.12.2017)	US
62/598,828	14 December 2017 (14.12.2017)	US

(71) Applicant: **ILLUSTRIS PHARMACEUTICALS, INC.**
[US/US]; 4030 Fabian Way, Suite B, Palo Alto, California
94030 (US).(72) Inventors: **WAUGH, Jacob M.**; 14 Point Loma Drive,
Corona Del Mar, California 92625 (US). **DAKE, Michael
D.**; 334 Gerona Avenue, Palo Alto, California 94301 (US).(74) Agent: **SRINIVAS, Harish** et al.; Pepper Hamilton LLP,
Union Trust Building, 501 Grant Street, Suite 300, Pitts-
burgh, Pennsylvania 15219-4429 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY




FIG. 1A




FIG. 1B

(57) Abstract: Compositions for topical delivery of an active agent and meth-
ods for using such compositions are described herein. Compositions include
one or more active agents and about 0.001 wt. % to about 10 wt. % of an extracel-
lular matrix component having average molecular weight of about 2,000 dal-
tons to about 20,000 daltons. The extracellular components include hyaluronic
acid, collagen, fibronectin, elastin, lectin, and fragments thereof and combina-
tions thereof.

[Continued on next page]

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*